...
首页> 外文期刊>Obstetrics and Gynecology: Journal of the American College of Obstetricians and Gynecologists >Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis.
【24h】

Overexpression of karyopherin-2 in epithelial ovarian cancer and correlation with poor prognosis.

机译:karyopherin-2在上皮性卵巢癌中的过表达及其与不良预后的关系。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVES: To evaluate karyopherin 2 (KPNA2) as a biomarker for epithelial ovarian cancer. METHODS: A candidate oncogene, KPNA2, was identified in gene microarray assays of epithelial ovarian cancer tissues compared with normal human ovarian surface epithelial tissues. Differences in expression were further validated by real-time polymerase chain reaction and Western blotting. KPNA2 expression patterns in epithelial ovarian cancer tissues were determined using immunohistochemistry and were compared with specific clinicopathologic features of the patient specimens analyzed. Factors associated with patient survival were also statistically analyzed. RESULTS: KPNA2 was found to be upregulated approximately eightfold in epithelial ovarian cancer tissues compared with human ovarian surface epithelial tissues, and overexpression was detected at the level of both transcription and translation. Immunohistochemical assays detected positive KPNA2 expression (++ or +++) in 50 of 102 (49.0%) epithelial ovarian cancer specimens, whereas negative KPNA2 expression (- or +) was observed in all of the human ovarian surface epithelial tissues analyzed. KPNA2 overexpression was also found to be significantly associated with specific histologic type, an advanced stage, a high histologic grade, and tumor recurrence (P<.05). The 5-year overall survival rate for KPNA2-negative compared with KPNA2-positive patients was 73.1% and 60.5%, respectively (P<.05). CONCLUSION: KPNA2 may play an important role in the development, differentiation, and carcinogenesis of epithelial ovarian cancer and therefore could be an indicator of poor prognosis for patients with epithelial ovarian cancer. LEVEL OF EVIDENCE: II.
机译:目的:评估核蛋白2(KPNA2)作为上皮性卵巢癌的生物标志物。方法:与正常人卵巢表面上皮组织相比,在上皮性卵巢癌组织的基因芯片检测中鉴定了候选癌基因KPNA2。表达差异通过实时聚合酶链反应和蛋白质印迹进一步证实。使用免疫组织化学确定上皮性卵巢癌组织中的KPNA2表达模式,并将其与所分析患者标本的特定临床病理特征进行比较。还统计分析了与患者生存相关的因素。结果:与人卵巢表面上皮组织相比,KPNA2在上皮性卵巢癌组织中被上调约八倍,并且在转录和翻译水平上均检测到过表达。免疫组织化学分析检测到102个上皮性卵巢癌标本中有5​​0个(49.0%)的KPNA2表达阳性(++或+++),而在分析的所有人类卵巢表面上皮组织中KPNA2表达均为阴性(-或+)。还发现KPNA2过表达与特定的组织学类型,晚期,高组织学等级和肿瘤复发显着相关(P <.05)。与KPNA2阳性患者相比,KPNA2阴性患者的5年总生存率分别为73.1%和60.5%(P <.05)。结论:KPNA2可能在上皮性卵巢癌的发生,分化和癌变中起重要作用,因此可能是上皮性卵巢癌患者预后不良的指标。证据级别:II。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号